Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes | Zendy

Zobair M. Younossi | Zendy; Maria Stepanova | Zendy; Tarik Asselah | Zendy; Graham R. Foster | Zendy; Keyur Patel | Zendy; Norbert Bräu | Zendy; Mark G. Swain | Zendy; Tram T. Tran | Zendy; Rafael Esteban | Zendy; M. Colombo | Zendy; Stephen Pianko | Zendy; Linda Henry | Zendy; Marc Bourlière | Zendy

Open Access

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes

Author(s) -

Zobair M. Younossi,

Maria Stepanova,

Tarik Asselah,

Graham R. Foster,

Keyur Patel,

Norbert Bräu,

Mark G. Swain,

Tram T. Tran,

Rafael Esteban,

M. Colombo,

Stephen Pianko,

Linda Henry,

Marc Bourlière

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix1106

Subject(s) - medicine , ledipasvir , sofosbuvir , ribavirin , regimen , gastroenterology , hepatitis c , hepatitis c virus , liver disease , daclatasvir , immunology , virus

While the necessity of treatment of hepatitis C virus (HCV)-infected patients with advanced liver disease is widely accepted, the benefit of treating patients without significant liver disease is less well established. Our aim was to assess the effect of treating HCV in patients with no or minimal fibrosis (Metavir stage F0-F1) on patient-reported outcomes (PROs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research